Compare AEVA & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | AMPH |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | 239 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 971.8M |
| IPO Year | N/A | 2005 |
| Metric | AEVA | AMPH |
|---|---|---|
| Price | $24.84 | $18.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $26.50 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 2.1M | 644.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $85.37 | $6.90 |
| Revenue Next Year | $132.72 | $4.64 |
| P/E Ratio | ★ N/A | $130.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.83 | $16.65 |
| 52 Week High | $38.79 | $31.26 |
| Indicator | AEVA | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 71.98 | 40.00 |
| Support Level | $12.37 | $17.03 |
| Resistance Level | N/A | $20.08 |
| Average True Range (ATR) | 2.45 | 0.81 |
| MACD | 0.60 | -0.21 |
| Stochastic Oscillator | 94.44 | 19.16 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.